Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › IPCALAB

IPCALAB

IPCA Laboratories Limited
Mid-capPharma ↗

What the six lenses say about IPCALAB — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1959.1
2026-09-08
VWAP · 1Y anchor
₹1595
+22.9% from VWAP
P/E · TTM
43.6×
TTM EPS ₹45.0
52-week range
96%
position low→high
RSI(14)
64
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How IPCALAB’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
6.0
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
TechnicalD990›

The actual numbers

Price vs VWAP (1y)+22.9%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+20.2%
Price vs 50-EMA+7.2%
RSI(14)64
RS vs Nifty 500 · 3M+14.3%
RS vs sector · 3M+8.3%
52-week range96%
Volume vs 30d avg0.30×
Volume vs 60d avg0.40×
ATR(14) · volatility58.7
Bollinger width · vol contraction0.152
FundamentalD556›

The actual numbers

Return on equity (ROE)16.0%
Return on capital (ROCE)17.3%
Operating margin17.1%
Net margin12.3%
Revenue growth · YoY+7.9%
EPS growth · YoY+54.7%
Debt / equity0.10×

Full 8-quarter history in the financials table below.

ValuationD412›

The actual numbers

P/E (TTM)43.6×
TTM EPS₹45.0
52-week range96%
CatalystD127›

The actual numbers

Earnings & momentum24
Capital actions18
Governance54

Every filing in the corporate-announcements panel below.

FlowD342›

The actual numbers

Promoter holding44.7%
Delivery · 30d avg49.0%
Up/down-day asymmetry-5.9pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D9 + D3 ) ÷ 2 = 6.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
85
Conviction score 85/100 · avg-decile strength 6.0/10
Conviction score85/100›
TechnicalD9›
FundamentalD5›
ValuationD4›
CatalystD1›
FlowD3›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.2pp
+0.5pp
+16.4pp
+15.9pp
+33.9pp
+52.4pp
Nifty 500
Broad-market baseline
+0.1pp
+0.5pp
+15.4pp
+14.3pp
+28.1pp
+47.2pp
Sector
Own-sector index
—
—
+12.6pp
+8.3pp
+15.0pp
+26.4pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

IPCALAB daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1959.10-6.20

Relative strength

RS vs baseline · rebased to 100

IPCALAB ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
141.65+0.15

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)2,0932,3552,2452,2472,3092,5562,3922,388
↳ change QoQ—+12.5%-4.7%+0.1%+2.8%+10.7%-6.4%-0.2%
EBITDA (₹cr)413468483429416545533484
EBITDA margin19.8%19.9%21.5%19.1%18.0%21.3%22.3%20.3%
PAT (₹cr)19924627664233281364307
↳ change QoQ—+23.4%+12.5%-76.8%+264.1%+20.6%+29.5%-15.7%
Net margin9.5%10.4%12.3%2.9%10.1%11.0%15.2%12.9%
EPS (₹)7.589.059.782.679.1911.1412.8611.79
D/E————————
YoY growth · Mar '26Revenue +6.3% YoYPAT +379.7% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 17 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 6 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 17 Jul '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Jul '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Jul '26
    MEDIUMcapital
    Credit Rating
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 26 Jun '26
    HIGHcapital
    Amalgamation/Merger
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 26 Jun '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 12 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Jun '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    MEDIUMcapital
    Dividend
    ›

    A dividend declaration — a cash return to shareholders.

    View original filing on NSE ↗
  • 29 May '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds IPCALAB

Mutual funds holding IPCALAB (10)

FundWeightAUM ₹crGrade
HDFC Mid Cap Gr3.01%1,05,143
Kotak Midcap Reg Gr3.12%69,283
Nippon India Growth Md Cp Reg Gr PlGrOpt1.07%50,751
Nippon India Growth Mid Cap Dir Bns1.07%50,751
Nippon India Growth Md Cp Reg Gr Bns1.07%50,751
Axis Midcap Gr2.03%34,404
Kotak Large & Midcap Reg Gr1.38%32,050
HDFC Large and Mid Cap Gr0.82%30,099
UTI Flexi Cap Reg Gr0.90%24,036
HDFC Multi Cap Reg Gr0.51%20,583

ETFs holding IPCALAB (10)

ETFWeightGrade
Nippon India Nifty Pharma ETF2.45%
DSP Nifty Healthcare ETF2.12%
Aditya BSL Nifty Healthcare ETF2.11%
Axis NIFTY Healthcare ETF2.11%
ICICI Pru Nifty Healthcare ETF2.11%
Mirae Asset Nifty 500 Healthcare ETF1.75%
Motilal Oswal BSE Healthcare ETF1.51%
Nippon India ETF Nifty Midcap 1500.58%
ICICI Pru Nifty Midcap 150 ETF0.58%
Mirae Asset Nifty Midcap 150 ETF0.58%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma